Literature DB >> 15356792

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

Alexander Imhof1, S Arunmozhi Balajee, David N Fredricks, Janet A Englund, Kieren A Marr.   

Abstract

Infection with voriconazole-resistant fungi may become problematic, because organisms with decreased susceptibility have been noted. Breakthrough fungal infections occurred in 13 of 139 patients who received voriconazole at our center during the period of September 1998 through September 2003. Zygomycetes were found in 6 patients, and Candida glabrata bloodstream infection occurred in 4 patients. Minimal inhibitory concentrations were > or =1 microg/mL for all available isolates. Yeasts and molds with decreased susceptibility to voriconazole may cause invasive infection in patients treated successfully for aspergillosis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15356792     DOI： 10.1086/423274

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  82 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation.

Authors:  Michelle A Barron; Margaret Lay; Nancy E Madinger
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 3.  Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.

Authors:  Juliette Pavie; Claire Lacroix; Dea Garcia Hermoso; Marie Robin; Christèle Ferry; Anne Bergeron; Martine Feuilhade; Françoise Dromer; Eliane Gluckman; Jean-Michel Molina; Patricia Ribaud
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Clara Baldin; Laura Kovanda; Nathan P Wiederhold; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

5.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

7.  Impact of zygomycosis on microbiology workload: a survey study in Spain.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Patricia Muñoz; Ignacio Gadea; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2007-03-28       Impact factor: 5.948

8.  Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

Authors:  Ana Alastruey-Izquierdo; Maria Victoria Castelli; Isabel Cuesta; Araceli Monzon; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

9.  Zygomycosis: an emerging fungal infection with new options for management.

Authors:  Carol A Kauffman; Anurag N Malani
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

10.  Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.